Vera Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
VERA$30.61+2.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(in thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Cash flows from operating activities | |||
| Net loss | $(299,615) | $(152,148) | $(95,990) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Depreciation and amortization | 468 | 105 | 21 |
| Accretion of discount and amortization of premium on debt securities, net | (6,981) | (8,972) | (4,433) |
| Accretion of loan exit fee and amortization of loan costs, net | 1,857 | 810 | 326 |
| Reduction in the carrying amount of operating lease right-of-use assets | 1,449 | 2,064 | 2,224 |
| Stock-based compensation | 37,926 | 20,802 | 11,493 |
| Payment of VT-109 license fee | 800 | — | — |
| Changes in operating assets and liabilities: | |||
| Prepaid expense and other current assets | (3,928) | 981 | 173 |
| Other assets | 51 | 351 | (262) |
| Accounts payable | 13,910 | (3,453) | (873) |
| Accrued and other current liabilities | 14,442 | 7,188 | (2,215) |
| Operating lease liabilities | (1,483) | (2,407) | (2,645) |
| Net cash used in operating activities | (241,104) | (134,679) | (92,181) |
| Cash flows from investing activities | |||
| Payment of VT-109 license fee | (800) | — | — |
| Purchase of property and equipment | (630) | (972) | (63) |
| Purchase of marketable securities | (310,446) | (703,015) | (224,930) |
| Proceeds from maturities of marketable securities | 506,162 | 274,958 | 176,019 |
| Proceeds from sale of marketable securities | — | 4,000 | 9,543 |
| Net cash provided by (used in) investing activities | 194,286 | (425,029) | (39,431) |
| Cash flows from financing activities | |||
| Proceeds from exercise of stock options and employee stock purchase plan | 6,981 | 13,413 | 1,056 |
| Proceeds from refinancing under loan and security agreement, net | 23,338 | — | — |
| Payment of deferred issuance costs related to unfunded loan commitments | (3,517) | — | |
| Proceeds from short swing settlement | 500 | 37 | — |
| Proceeds from borrowings, net of costs | — | — | 24,741 |
| Repurchase of common stock | — | (13) | — |
| Proceeds from issuance of common stock in follow-on offerings | 300,000 | 632,500 | 115,000 |
| Payment of issuance costs and underwriting fees related to follow-on offerings | (18,405) | (39,264) | (7,256) |
| Net cash provided by financing activities | 308,897 | 606,673 | 133,541 |
| Net increase in cash and cash equivalents | 262,079 | 46,965 | 1,929 |
| Cash and cash equivalents, beginning of year | 92,646 | 45,681 | 43,752 |
| Cash and cash equivalents, end of year | $354,725 | $92,646 | $45,681 |
| Supplemental disclosure of cash flow information | |||
| Cash paid for interest expense | $6,720 | $6,652 | $3,352 |
| Purchases of property and equipment included in accounts payable | $252 | $— | $— |
| Follow-on offering costs included in accounts payable | $71 | $— | $— |
| Follow-on offering costs included in accrued and other liabilities | $343 | $— | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.